This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Taro, Sandoz fail to get quick appeal in states' US case over generic drug prices

( August 18, 2025, 16:44 GMT | Official Statement) -- MLex Summary: Taro Pharmaceuticals and Sandoz were denied leave to immediately appeal a judgment on liability in an antitrust case accusing them of conspiring over generic drug pricing. District Judge Michael P. Shea said that just because the court has not yet ironed out exactly how the jury instructions will read, or precisely which exhibits or testimony will be allowed at trial to contest areas related to the facts the court has found to be established in its ruling, does not mean, as Taro and Sandoz suggest, that the court has left "open" whether the companies' conduct has violated the prohibitions on price-fixing and market allocation. Statement follows in full:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections